China approves a fourth COVID-19 vaccine for emergency use


It is the fourth vaccine of its kind to be granted approval for emergency use. China has approved four vaccines developed by three Chinese companies for public use.

The vaccine was jointly developed by Anhui Zhifei Longcom Biopharm Pharmaceutical Co., Ltd. Ltd. And the Chinese Academy of Sciences. The team completed the first and second stages of clinical trials in October last year, and is currently conducting the final phase of trials in Uzbekistan, Pakistan and Indonesia, according to the statement.

The vaccine was approved for use in Uzbekistan on March 1.

The protein subunit vaccine is similar to many other globally approved vaccines in that it trains the body to recognize the spike protein that covers the surface of the coronavirus vaccine, although the difference lies in how it tells the body to recognize the vaccine. protein. Scientists grow a harmless version of the protein in cells and then purify it before assembling it into a vaccine and injecting it.

There is no publicly available information in peer-reviewed journals on clinical trial data demonstrating efficacy or safety. A company spokesperson said the data could not be shared at this time but the company was actively providing the information to health authorities.

China has been slow to vaccinate its population of 1.4 billion, despite four vaccines approved for public use. The latest figures, according to government officials at a Monday press conference in Beijing, are that it has delivered 64.98 million doses of vaccines.

China has targeted what it considers key population groups to be vaccinated so far, that is, health care workers as well as those working at borders or customs, and specific industries selected by the government. The second group, which has been significantly absent thus far compared to many other countries, are the elderly and those with pre-existing conditions.

Vaccines were previously restricted to adults between the ages of 18 and 59, with officials citing a lack of clinical trial data for older adults, although the government appears to be indicating that limits are now set aside. “We will urgently undertake a comprehensive vaccination of the population concerned,” Li Bin, vice chairman of the National Health Commission, said on Monday.

The new China News Agency (Xinhua) reported over the weekend that in certain neighborhoods in Beijing, local health centers have begun offering vaccinations to people 60 and over.

Copyright 2021 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.

Like it? Share with your friends!


What's Your Reaction?

hate hate
confused confused
fail fail
fun fun
geeky geeky
love love
lol lol
omg omg
win win


Your email address will not be published. Required fields are marked *